Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon

 
In response to the escalating situation and war on Lebanon, the Ministry of Public Health (MoPH) has developed and is currently implementing with all stakeholders the:
“National Intersectoral MHPSS Emergency Preparedness and Response Plan: In the Context of the Risk of War on Lebanon "

Developed through a collaborative approach by the National Mental Health Programme (NMHP) with the support of the World Health Organization, UNICEF, and all MHPSS Stakeholders (please refer to the action plan for a full list), this comprehensive plan outlines a proactive approach to anticipating, mitigating, and responding to the psychosocial impacts by focusing on early intervention and support to minimize the adverse effects on individuals, healthcare personnel and communities. It underscores the commitment of the MoPH and the NMHP to safeguard mental health and respond timely and effectively to the psychosocial needs of all populations residing in Lebanon during times of crisis while promoting their resilience.

Key Features of the Plan:
  • Continuity of MHPSS Services: The plan highlights actions to ensure the continued availability and accessibility of MHPSS services across Lebanon.
  • Assurance of Psychotropic Medications: The plan emphasizes ensuring the continuous supply and access to psychotropic medications to all old and new beneficiaries.
  • Communication and Messaging: The plan prioritizes the development and dissemination of key messages and tips on topics related to mental health and well-being that would promote community resilience.
  • Training and Capacity Building: The plan places a strong emphasis on training healthcare professionals and frontline responders in MHPSS principles and practices to provide effective support to service users and providers.
The MoPH is implementing this action plan with all stakeholders, including governmental bodies, local authorities and municipalities, non-governmental organizations, healthcare providers, frontliners, and the international community - Please do reach out if your organization is interested to join in implementing this crucial plan and working together to ensure the mental health and psychosocial support of Lebanon’s residents during times of adversity.

Kindly find a selection of valuable links below:
    ...
    7
    ...
ATC Name B/G Ingredients Dosage Form Price
J01MA02 CIPROX G Ciprofloxacine (lactate) - 200mg/100ml 0.2%w/v Injectable solution 520,067 L.L
S02CA05 CETRAXAL PLUS G Ciprofloxacine HCl monohydrate - 3mg/ml, Fluocinolone acetonide - 0.25mg/ml Drops solution 795,555 L.L
L01XA01 CISPLATINE VIATRIS 1MG/ML G Cisplatin - 10mg/10ml 10mg/10ml Injectable concentrated solution 396,936 L.L
L01XA01 CISPLATINE VIATRIS 1MG/ML G Cisplatin - 50mg/50ml 50mg/50ml Injectable concentrated solution 1,134,720 L.L
N06AB04 CIPRAM B Citalopram - 20mg 20mg Tablet 2,280,501 L.L
N06BX06 CEROLINE G Citicoline - 100mg/ml 100mg/ml Solution 894,615 L.L
J01FA09 CLARIDAR DAR AL DAWA G Clarithromycin - 125mg/5ml 125mg/5ml Suspension 295,645 L.L
J01FA09 CLAMYCIN G Clarithromycin - 250mg 250mg Tablet, film coated 641,205 L.L
J01FA09 CLAREM 250 G Clarithromycin - 250mg 250mg Tablet, film coated 467,657 L.L
J01FA09 CLARIDAR DAR AL DAWA G Clarithromycin - 250mg/5ml 250mg/5ml Suspension 877,529 L.L
J01FA09 CLAREM 500 G Clarithromycin - 500mg 500mg Tablet, film coated 686,704 L.L
D10AF01 CLINIDERM G Clindamycin (phosphate) - 1% 1% Gel 712,876 L.L
J01FF01 CLINDAMYCIN VIANEX BA FREE G Clindamycin (phosphate) - 600mg/4ml 600mg/4ml Injectable solution 201,576 L.L
J01FF01 CLINDAMYCIN-HAMELN G Clindamycin (phosphate) - 600mg/4ml 150mg/ml Injectable solution 3,535,650 L.L
G01AA10 CLINDAMYCIN G Clindamycin - 100mg 100mg Ovule 712,876 L.L
D07AD01 CLOBEVAT G Clobetasol (propionate) - 0.05% 0.05% Cream 302,045 L.L
D07AD01 CLOBEVAT G Clobetasol (propionate) - 0.05% 0.05% Ointment 302,045 L.L
G03GB02 CLOMID B Clomifene citrate - 50mg 50mg Tablet 274,144 L.L
G03GB02 CLOMIFERT G Clomifene citrate - 50mg 50mg Tablet 395,090 L.L
G03GB02 CLOMIFERT G Clomifene citrate - 50mg 50mg Tablet 395,090 L.L
B01AC04 CERUVIN G Clopidogrel (Bisulfate) - 75mg 75mg Tablet 240,548 L.L
B01AC04 CLODOR G Clopidogrel (Bisulfate) - 75mg 75mg Tablet 1,148,025 L.L
B01AC04 CLOPI TAD G Clopidogrel (Bisulfate) - 75mg 75mg Tablet, film coated 911,125 L.L
B01AC04 CLOPIKEY G Clopidogrel (Bisulfate) - 75mg 75mg Tablet 748,520 L.L
B01AC04 CLOTRIX 75 G Clopidogrel (hydrogenosulfate) - 75mg 75mg Tablet, film coated 1,109,630 L.L
B01AC04 CLOTRIX 75 G Clopidogrel (hydrogenosulfate) - 75mg 75mg Tablet, film coated 1,035,399 L.L
B01AC04 CLOPIDOGREL ARROW G Clopidogrel besylate - 75mg 75mg Tablet, film coated 658,483 L.L
D01AC01 CANESTEN B Clotrimazole - 0.01g/g 0.01g/g Cream 344,024 L.L
D01AC01 CANESTEN B Clotrimazole - 0.01g/ml 0.01g/ml Solution 368,213 L.L
G01AF02 CANESTEN B Clotrimazole - 0.1g 0.1g Tablet 408,528 L.L
    ...
    7
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025